Phio Pharmaceuticals to Present at the H.C. Wainwr
Post# of 66
(Total Views: 905)
Posted On: 10/03/2019 8:11:23 AM
Phio Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Healthcare Conference
Tue September 3, 2019 7:10 AM|PR Newswire|About: PHIO
MARLBOROUGH, Mass., Sept. 3, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it will present at the H.C. Wainwright 21st Annual Healthcare Conference in New York City.
Dr. Gerrit Dispersyn, Dr. Med. Sc., President and CEO, will present an overview of the Company's RNAi technology and an update on the Company's development activities. The presentation will be held September 10, 2019, at 11:40 AM in the Kennedy II room (4th Floor) at the Lotte New York Palace Hotel. Dr. Dispersyn will also be available for investor and executive meetings throughout the conference.
The presentation will be webcast live and archived under the "Investors – Events and Presentations" section of the Company's website, www.phiopharma.com.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through our proprietary sd-rxRNA platform with utility in immune cells and/or the tumor micro-environment. Our goal is to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing immune effector cells to overcome tumor immune escape providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
https://seekingalpha.com/pr/17618751-phio-pha...conference
Tue September 3, 2019 7:10 AM|PR Newswire|About: PHIO
MARLBOROUGH, Mass., Sept. 3, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it will present at the H.C. Wainwright 21st Annual Healthcare Conference in New York City.
Dr. Gerrit Dispersyn, Dr. Med. Sc., President and CEO, will present an overview of the Company's RNAi technology and an update on the Company's development activities. The presentation will be held September 10, 2019, at 11:40 AM in the Kennedy II room (4th Floor) at the Lotte New York Palace Hotel. Dr. Dispersyn will also be available for investor and executive meetings throughout the conference.
The presentation will be webcast live and archived under the "Investors – Events and Presentations" section of the Company's website, www.phiopharma.com.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through our proprietary sd-rxRNA platform with utility in immune cells and/or the tumor micro-environment. Our goal is to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing immune effector cells to overcome tumor immune escape providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
https://seekingalpha.com/pr/17618751-phio-pha...conference
(0)
(0)